Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Thursday, April 20, 2017 Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
Thursday, April 20, 2017 Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
Upcoming and Recent Events > MORE
Date Title  
Thursday, May 4, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2017 Q1 Quarterly Earnings Call
Thursday, February 23, 2017
4:30 PM ET
Five Prime Therapeutics, Inc. 2016 Q4 Quarterly Earnings Call
Supporting Materials
PDF View Presentation 696.1 KB   Add to Briefcase
Thursday, February 16, 2017
11:00 AM ET
LEERINK Partners 6th Annual Global Healthcare Conference
Supporting Materials
PDF View Presentation  3.1 MB   Add to Briefcase

FPRX (Common Stock)

Change (%)

Data as of 4:00 PM ET on Friday, April 28, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.